Harmankaya O, Baştürk T, Oztürk Y, Karabiber N, Obek A
Department of Nephrology, Sişli Etfal Training and Research Hospital, Istanbul, Turkey.
Int Urol Nephrol. 2001;33(3):583-7. doi: 10.1023/a:1019546617485.
Primary membranoproliferative glomerulonephritis (MPGN) has a poor long-term prognosis, with 40 per cent of patients reaching end-stage renal failure after 10 years of observation. Approximately 35 per cent of patients die due to complications of the nephrotic syndrome. This study investigates the effect of acetylsalicylic acid (ASA) combined with dipyridamole on proteinuria and renal function in nephrotic MPGN patients with normal/moderately reduced glomerular filtration rate (GFR). Fourteen patients with biopsy-proven type I MPGN received ASA (1000 mg/day) and dipyridamole (300 mg/day) for 24 months. Proteinuria was reduced from 6.8 +/- 2.4 g/day to 1.1 +/- 0.6 g/day (p < 0.001). Serum albumin levels increased from 2.2 +/- 0.5 g/dL to 3.7 +/- 0.4 g/dL (p < 0.001) during the study period after 24 months compared to baseline. Serum creatinine and GFR did not significantly change in patients treated with acetylsaliclylic acid and dipyridamole during the observation period (p < 0.05). Our study suggests that ASA combined with dipyridamole significantly reduces proteinuria without impairing renal function in patients with MPGN.
原发性膜增生性肾小球肾炎（MPGN）的长期预后较差，经过10年观察，40%的患者会发展为终末期肾衰竭。约35%的患者死于肾病综合征的并发症。本研究调查了乙酰水杨酸（ASA）联合双嘧达莫对肾小球滤过率（GFR）正常/轻度降低的肾病性MPGN患者蛋白尿和肾功能的影响。14例经活检证实为I型MPGN的患者接受了24个月的ASA（1000毫克/天）和双嘧达莫（300毫克/天）治疗。蛋白尿从6.8±2.4克/天降至1.1±0.6克/天（p<0.001）。与基线相比，在24个月的研究期后，血清白蛋白水平从2.2±0.5克/分升升至3.7±0.4克/分升（p<0.001）。在观察期内，接受乙酰水杨酸和双嘧达莫治疗的患者血清肌酐和GFR无显著变化（p<0.05）。我们的研究表明，ASA联合双嘧达莫可显著降低MPGN患者的蛋白尿，且不损害其肾功能。
